Promising targets in rectal cancer include carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5, from here on to be referred to as CEA), epithelial cell adhesion molecule (EpCAM), αvβ6 integrin, and urokinase-type plasminogen activator receptor (uPAR) [14,15,16,17]. This evidence concerns the gene EPCAM and rectal cancer.